Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the GeneFinder COVID-19 plus (Elitech) and the diagnosis of the infectious disease specialist respectively. Four samples display a Ct < 22.0 for the E and RdRp genes while the N gene was not detected, suggesting a variability of the viral sequence. There was no cross-reactivity with other respiratory viruses. The Allplex 2019-nCoV appears as a reliable method, but additional evaluations using more samples are needed. RT-PCR assays should probably include at least 2 viral targets.

有几种针对 SARS-CoV-2 RT-PCR 的商业化验方法可用，但其中很少有人进行评估。我们使用 41 个鼻咽样本评估 Allplex 2019-nCoV (Seegene) 检测。GeneFinder COVID-19 plus (Elitech) 和传染病专家诊断的一致率分别为 92.7% 和 100%。四个样本显示E和RdRp基因的 Ct < 22.0，而未检测到N基因，表明病毒序列存在变异性。与其他呼吸道病毒没有交叉反应。Allplex 2019-nCoV 似乎是一种可靠的方法，但需要使用更多样本进行额外评估。RT-PCR 分析可能应包括至少 2 个病毒靶标。